Table 1.
In vitro activity of KAA-2 against various influenza strains.
| Virus | Strain | EC50 (nM) | Antiviral indexa |
|---|---|---|---|
| Influenza A | PR8/34 (H1N1) | −b | − |
| FM/1/47 (H1N1) | 11.52 ± 1.05 | >87.0 | |
| Kyoto/1/81 (H1N1) | 5.36 ± 0.38 | >186.6 | |
| Bangkok/10/83 (H1N1) | 3.59 ± 0.27 | >278.6 | |
| Beijing/262/95 (H1N1) | 5.42 ± 0.46 | >184.5 | |
| Oita/OU1 P3-3/09 (H1N1) | 12.30 ± 0.24 | >81.3 | |
| WSN/33 (H1N1) | 68.56 ± 4.17 | >14.6 | |
| Aichi/2/68 (H3N2) | 13.59 ± 1.04 | >73.6 | |
| Udorn/72 (H3N2) | 3.86 ± 0.09 | >259.1 | |
| Philippines/2/82 (H3N2) | 4.40 ± 0.27 | >227.3 | |
| Influenza B | Ibaraki/2/85 | 1.71 ± 0.97 | >584.6 |
The IC50 value of KAA-2, determined using MDCK cells, was >1000 (nM).
a
The antiviral index represents the ratio of IC50 to EC50.
b
PR8/34 was insensitive to KAA-2 up to 75 nM, a highest dose in this experiment.